Tempus will work with the center to develop personalized medicine regimens for cancer patients, initially focusing on hematological and pancreatic malignancies.
The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses.
The Mayo Medical Laboratories laboratory is offering mate-pair sequencing for cancer and inherited disease indications, with plans to expand the service.
The two companies are expanding a long-term collaboration to include development and commercialization of assays for the Applied Biosystems 3500Dx system.
The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.
The Mayo team aims to launch MP-seq for hematological malignancies and constitutional diseases in the next year and for solid tumors one year later.
The assays have CE marking to run on either Illumina's MiSeq or Thermo Fisher's Ion PGM.
N-of-One will provide interpretation services for BloodCenter of Wisconsin's HemeOnc panel
MGH runs the clinical fusion assay for all lung cancer patients and the Snapshot NGS test on all patients with solid tumors. It is planning to expand the assays and is also developing a fusion panel for hematological malignancies.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.
In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.
Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.